Provided are a drug for treating artery-related diseases and the use thereof. Specifically, provided are the use of a class of compounds of formula I in the treatment of artery-related diseases. Experiments show that the compounds of formula I have a significant effect on aneurysm, intramural hematoma and/or atrerial dissection.

Provided are a drug for treating artery-related diseases and the use thereof. Specifically, provided are the use of a class of compounds of formula I in the treatment of artery-related diseases. Experiments show that the compounds of formula I have a significant effect on aneurysm, intramural hematoma and/or atrerial dissection.

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and/or treatment of bacterial infections and antibacterial-induced dysfunctions. The invention is based on the identification of compounds that prevent antibacterial effects of antibiotics on microbiome-bacterial species, while retaining antibacterial effects of antibiotics on pathogenic bacteria. The invention also pertains to pharmaceutical compositions comprising antibiotics and antibiotic antidotes for the protection of commensal microbiome-bacteria. Thus, this invention relates to compounds and pharmaceutical combinations useful to prevent antibiotic-induced adverse effects on the gut microbiome. Furthermore provided are methods for preventing an adverse effect on a gut microbiome using the compounds and/or pharmaceutical compositions of this invention.

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and/or treatment of bacterial infections and antibacterial-induced dysfunctions. The invention is based on the identification of compounds that prevent antibacterial effects of antibiotics on microbiome-bacterial species, while retaining antibacterial effects of antibiotics on pathogenic bacteria. The invention also pertains to pharmaceutical compositions comprising antibiotics and antibiotic antidotes for the protection of commensal microbiome-bacteria. Thus, this invention relates to compounds and pharmaceutical combinations useful to prevent antibiotic-induced adverse effects on the gut microbiome. Furthermore provided are methods for preventing an adverse effect on a gut microbiome using the compounds and/or pharmaceutical compositions of this invention.

Provided is 4-methylumbelliferone, derivatives and salts thereof, or a composition comprising same for use in the treatment of a condition of the nervous system in a subject. Preferably, the condition is one associated with a scar, such as a glial scar. Typically, the condition of the nervous system is selected from the group comprising conditions caused by trauma, injury, infection, degeneration, structural defects, tumours, blood flow disruption. The neural and other lesions are made permeable and repairable.

The present invention relates to a method for virus assay. More closely the invention relates a method for total quantification of adenovirus in a sample as well as total and functional (active) adenovirus in a sample. The method for determining adenovirus concentration in a sample comprises subjecting said sample to SPR (surface plasmon resonance) assay with immobilized FX (Factor X) and/or immobilized CAR (coxsackievirus and adenovirus receptor) on a sensor surface, wherein the adenovirus concentration is determined from sample binding to immobilized FX and/or immobilized CAR. CAR can be replaced by an ligand binding to adenovirus fiber, such as an anti-adenovirus fiber antibody. FX can be replaced by a ligand binding to adenovirus hexon, such as an anti-adenovirus hexon antibody. The method can be used for quality control in an adenovirus purification process, for example for gene therapy.

The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.

The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.

This invention pertains to an anti-microbial, in particular anti-bacterial, more particularly against Gram negative bacteria, and/or anti-fungal composition comprising as active blend trans-cinnamaldehyde and a potentiating agent. In particular this composition is intended for preventing and/or treating microbial infection in an animal.

This invention pertains to an anti-microbial, in particular anti-bacterial, more particularly against Gram negative bacteria, and/or anti-fungal composition comprising as active blend trans-cinnamaldehyde and a potentiating agent. In particular this composition is intended for preventing and/or treating microbial infection in an animal.